Researchers at the University of Colorado Anschutz Medical Campus have uncovered a critical, previously underappreciated role for B cells in vaccine protection. Best known for producing antibodies, B cells also guide other immune cells, specifically CD8 T …

… it diabetes? Is it multiple sclerosis? Is it attention deficit disorder? … from inside anti-vaccine groups on Facebook. -Recognizing that … 147 people in 2015. -Vaccines are one of the very … . -Hundreds of anti-vaccine protesters swarmed the Capitol again. …

Invasive perioperative procedures often trigger an inflammatory response in patients, stimulating immune regulatory mechanisms in their bodies. Patients’ immune function gradually declines as they age due to the degeneration of immune organs, chronic …

A Marin researcher has received one of science’s highest honors for a surprising, transformative discovery about multiple sclerosis that offers hope of freeing those with the chronic illness from its debilitating effects. Dr. Stephen Hauser, a 33-year Ross …

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy …

Vanessa Abraham had spent her entire career helping people find their voices. So she felt it was a cruel twist of fate when she contracted a rare neurological disease that took away her ability to speak and left her paralyzed. Mrs Abraham, 45 from  …

(MENAFN- GlobeNewsWire - Nasdaq) Monoclonal Antibodies Set to Be Fastest-Growing Carrier Segment in ADDS Market, With 8.9% CAGR Driven by Antigen-Specific Therapies Dublin, May 01, 2025 (GLOBE NEWSWIRE) -- The "Advanced Drug Delivery Systems - A …

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive …

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of …

Investigators have shared the study design of ENABLE, the first phase 4, post-marketing observational trial (NCT06433752) assessing ublituximab (Briumvi; TG Therapeutics), one of the more newly approved medications for relapsing multiple sclerosis that …